SARMs and CBD: Navigating Regulatory Gaps in UK's Food Industry - Unusual products blur the lines between food and medicine, prompting questions about effective regulation.
Dr. Christian Löfke, researcher and product developer at BioBloom in Austria explains why hemp protein is gaining a reputation as nutraceutical product.
CBD oil has long been utilised for its various therapeutic effects, but what about its effect on cancer? Read on to find out more about what the research shows.
Andreas Met, COO, Compliance and Director at Halo Labs highlights how the use of medical cannabis is on the rise in the UK and could offer relief to many NHS patients.
Dr Charlie Easmon from Your Excellent Health Service gives a medical professional’s opinion on medical marijuana in the UK, including comment on hemp, CBD and THC.
Professor Mike Barnes, Co-Founder of Maple Tree Consultancy states that the UK’s clinicians need training in medical cannabis and explains precisely why this should be.
Dr. Christian Löfke, researcher and product developer at BioBloom in Austria explains CBG (cannabigerol), a “new” cannabinoid with vast potential in cannabis research.
Here, we talk to Professor Trevor Jones at the European Medical Cannabis Association (EUMCA) about storing CBD, clinical trials post-Brexit and the UK-US trade deal.
Associate, David Hardstaff and Partner, John Binns at BCL Solicitors LLP, explain here how cannabis wonder child takes a knock in light of the European Commission’s ‘pause’ on CBD novel food applications mean for this booming industry.
